Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Blood

Topics

Medicine

Immunology

Genetics

Pathology And Forensic Medicine

Public Health, Environmental And Occupational Health

Show all topics

DOI

10.1182/blood-2024-210301